Endothelial dysfunction and erectile dysfunction in the aging man: Review Article

International Journal of Urology

Volumn 17, Issue 1, 2010, Pages 38-47

  Aversa, Antonio ^a,b   Bruzziches, Roberto ^b   Francomano, Davide ^b   Natali, Marco ^b   Gareri, Pietro ^c   Spera, Giovanni ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ASP Catanzaro   (Italy)

Author keywords

Cardiovascular risk factors; Endothelial dysfunction; Erectile dysfunction; Nitric oxide; Phosphodiesterase type 5 inhibitors

Indexed keywords

SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

AGING; ANDROGEN DEPRIVATION THERAPY; CLINICAL TRIAL; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATECTOMY; REVIEW;

AGING; ENDOTHELIUM, VASCULAR; HUMANS; IMPOTENCE, VASCULOGENIC; INSULIN RESISTANCE; MALE; TESTOSTERONE;

EID: 74049092278     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02426.x     Document Type: Review

References (94)

1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 84 : 450 456.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979 241 : 2035 2038.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998 339 : 229 234.
4. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 2005 258 : 250 256.
5. 2: erectile dysfunction = Endothelial dysfunction. Endocrinol. Metab. Clin. North Am. 2007 36 : 453 463.
6. Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. A potential protective role for statins and 5-phosphodiesterase inhibitors. J. Am. Coll. Cardiol. 2008 51 : 2040 2044.
7. Akilli H, Gok H, Soylu A, Kayrak M. Severity of coronary artery disease and symptoms of erectile dysfunction in males with a positive exercise treadmill test. Int. J. Urol. 2007 14 : 733 737.
8. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and - independent vasodilation in men with erectile dysfunction and no other clinical CVD. J. Am. Coll. Cardiol. 2004 43 : 179 184.
9. Thompsom IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent CVD. JAMA 2005 294 : 2996 3002.
10. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000 101 : 1899 1906.
11. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., Lerman A. A long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000 101 : 948 954.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 362 : 801 809.
13. Russell S, Nehra A. The physiology of erectile dysfunction. Herz 2003 28 : 277 283.
14. Brunner H, Cockcroft JR, Deanfield J et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005 23 : 233 246. (Pubitemid 40279622)
15. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 168 175.
16. Blankenberg S, Rupprecht HJ, Bickel C et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001 104 : 1336 1342.
17. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van Poppel G, Bots ML. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 2003 170 : 147 153.
18. Traish AM, Abu-Zahra H, Guay AT. The brain, the penis and steroid hormones: clinical correlates with endothelial dysfunction. Curr. Pharm. Des. 2008 14 : 3723 3736.
19. Browne D, Meeking D, Shaw K. Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes - pathogenesis and identification. Br. J. Diabetes 2003 3 : 27 34. (Pubitemid 37045605)
20. Elesber AA, Solomon H, Lennon RJ et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur. Heart. 2006 27 : 824 831.
21. Baumhakel M, Werner N, Bohm M, Nickenig G. Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur. Heart. 2006 27 : 2184 2188.
22. Kielstein JT, Frolich JC, Haller H, Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol. Dial. Transplant. 2001 16 : 1742 1745.
23. Schiel R, Franke S, Busch M et al. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur. J. Med. Res. 2003 8 : 283 291.
24. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006 113 : 1888 1904.
25. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur. Heart J. 2003 24 : 1912 1919.
26. Wierzbicki AS, Solomon H, Lumb PJ, Lyttle K, Lambert-Hammill M, Jackson G. Asymmetrical dimethylarginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006 185 : 421 425.
27. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 2002 39 : 257 265.
28. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 1995 26 : 1235 1241.
29. Wu WC, Sharma SC, Choudhary G, Coulter L, Coccio E, Eaton CB. Flow-mediated vasodilation predicts the presence and extent of coronary artery disease assessed by stress thallium imaging. J. Nucl. Cardiol. 2005 12 : 538 544.
30. Yavuz BB, Yavuz B, Sener DD et al. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology 2008 54 : 153 156.
31. Farouque HMO, Meredith IT. The assessment of endothelial function in humans. Coron. Artery Dis. 2001 12 : 445 454.
32. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002 106 : 640 642.
33. Hamburg NM, Keyes MJ, Larson MG et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008 117 : 2467 2474.
34. Aversa A, Francomano D, Bruzziches R, Pili M, Natali M, Spera G. The application of digital pulse amplitude in the diagnostic investigation of patients with erectile dysfunction. Andrologia (in press).
35. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am. J. Cardiol. 2005 96 : 13M 18M.
36. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 2006 22 : 423 436.
37. Akishita M, Hashimoto M, Ohike Y. Low testosterone level is an independent determinant of EDys in men. Hypertens. Res. 2007 30 : 1029 1034.
38. Aversa A, Rossi F, Francomano D et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int. J. Impot. Res. 2008 20 : 566 573.
39. Gooren LJG. The age-related decline of androgen levels in men: clinically significant? Br. J. Urol. 1996 78 : 763.
40. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin. Endocrinol. (Oxf.) 2004 60 : 653 670.
41. Jones TH. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur. Urol. 2007 6 : 847 857.
42. Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am. J. Physiol. Endocrinol. Metab. 2006 290 : E234 42.
43. Fukui M, Kitagawa Y, Ose H, Hasegawa G, Yoshikawa T, Nakamura N. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr. Diabetes Rev. 2007 3 : 25 31.
44. Rosano GM, Sheiban I, Massaro R et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int. J. Impot. Res. 2007 19 : 176 182.
45. Hak AE, Witteman JC, de Jong FH. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J. Clin. Endocrinol. Metab. 2002 87 : 3632 3639.
46. Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J. Intern. Med. 2006 259 : 576 582.
47. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 2008 93 : 68 75.
48. Capaldo B, Patti L, Oliviero U et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 1997 82 : 1378 1381.
49. Simon D, Charles MA, Nahoul K et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J. Clin. Endocrinol. Metab. 1997 82 : 682 685.
50. Akishita M, Hashimoto M, Ohike Y et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens. Res. 2008 31 : 69 74.
51. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002 60 : 201 208.
52. Basaria S, Lieb J II., Tang A et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin. Endocrinol. 2002 56 : 779 786.
53. Shahani S, Braga-Basaria M, Basaria S. Androgen Deprivation therapy in prostate cancer & metabolic risk for atherosclerosis. J. Clin. Endocrinol. Metab. 2008 93 : 2042 2049.
54. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 2007 25 : 2420 2425.
55. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006 24 : 4448 4456.
56. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 : 1493 1500.
57. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl. Cancer Inst. 2007 99 : 1516 1524.
58. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008 299 : 289 295.
59. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 2007 18 : 9 13. (Pubitemid 44973750)
60. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone and testosterone on Ca2+ entry mechanism of coronary vasoconstriction. Arterioscler. Thromb. Vasc. Biol. 1999 19 : 1034 1040.
61. Murphy JG, Khalil RA. Decreased [Ca2]i during inhibition of coronary smooth muscle contraction by 17b-estradiol, progesterone, and testosterone. J. Pharmacol. Exp. Ther. 1999 291 : 44 52.
62. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995 91 : 1154 1160.
63. Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J. Pharm. Exp. Ther. 1996 277 : 349 354.
64. Perusquia M, Hernandez R, Morales MA, Campos MG, Villalon MG. Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen. Pharmacol. 1996 27 : 181 185. (Pubitemid 26076862)
65. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by calcium antagonist action. J. Endocrinol. Invest. 2002 25 : 455 458.
66. Tep-areenan P, Kendall DA, Randall MD. Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br. J. Pharmacol. 2002 135 : 735 740.
67. Yildiz O, Seyrek M, Irkilata HC, Yildirim I, Tahmaz L, Dayanc M. Testosterone might cause relaxation of human corpus cavernosum by potassium channel opening action. Urology 2009 74 : 229 232.
68. Isidori AM, Giannetta E, Gianfrilli D et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. (Oxf.). 2005 63 : 381 394.
69. Lue TF. Erectile dysfunction. N. Engl. J. Med. 2000 342 : 1802 1813.
70. Bortolotti A, Parazzini F, Colli E. The epidemiology of erectile dysfunction and its risk factors. Int. J. Androl. 1997 20 : 323 334.
71. Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J. Am. Coll. Cardiol. 2005 46 : 1503 1506.
72. Lojanapiwat B, Weerusawin T, Kuanprasert S. Erectile dysfunction as a sentinel marker of endothelial dysfunction disease. Singapore Med. J. 2009 50 : 698 701.
73. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the 'Tip of the iceberg' of a systemic vascular disorder? Eur. Urol. 2003 44 : 352 354.
74. Lakatta EG, Yin FCP. Myocardial aging: functional alterations and related cellular mechanisms. Am. J. Physiol. 1982 242 : H927 41.
75. Singh N, Prasad S, Singer DRJ, Macallister RJ. Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. Clin. Sci. 2002 102 : 595 600.
76. Yavuz BB, Yavuz B, Sener DD, Cankurtaran M, Halil M, Ulger Z. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology 2008 54 : 153 156.
77. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am. Heart J. 2003 145 : 943 951.
78. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in elderly healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 1994 24 : 471 416.
79. Fernandez-Cruz A, Martin P, Fernandez L et al. Plasma endothelin is increased in young essential hypertensives but not in elderly essential or diabetic hypertensives. J. Hypertens. 1993 11 : S146 7.
80. Dede DS, Yavuz B, Yavuz BB et al. Assessment of endothelial function in Alzheimer's disease: is Alzheimer's disease a vascular disease? J. Am. Geriatr. Soc. 2007 55 : 1613 1617.
81. Sato Y, Tanda H, Kato S, Onishi S, Nitta T, Koroku M. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int. J. Urol. 2007 14 : 339 342.
82. Kimoto Y, Nagao K, Sasaki H et al. JSSM Guidelines for erectile dysfunction. Int. J. Urol. 2008 15 : 564 576.
83. Masuda H. Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition disorders and erectile dysfunction. Int. J. Urol. 2008 15 : 128 134.
84. Behr-Roussel D, Oudot A, Caisey S et al. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur. Urol. 2008 53 : 1272 1280.
85. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007 56 : 1025 1033.
86. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J. Androl. 2007 9 : 134 141.
87. Padma-Nathan H, McCullough AR, Levine LA et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int. J. Impot. Res. 2008 20 : 479 486.
88. Montorsi F, Brock G, Lee J et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur. Urol. 2008 54 : 924 931.
89. Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE Study. Eur. Urol. 2008 54 : 204 212.
90. Bruzziches R, Greco EA, Pili M, Francomano D, Spera G, Aversa A. Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. Curr. Diabetes Rev. 2008 4 : 24 30.
91. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 2001 39 : 151 158.
92. Berger AP, Deibl M, Leonhartsberger N et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005 96 : 1073 1078. (Pubitemid 41531417)
93. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int. 2006 97 : 23 8.
94. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J. Sex. Med. 2009 6 : 1794 1808.